Last reviewed · How we verify
OPC-34712 [Brexpiprazole] High Dose
Brexpiprazole is a partial agonist at serotonin 5-HT1A receptors and a partial agonist at dopamine D2 receptors.
Brexpiprazole is a partial agonist at serotonin 5-HT1A receptors and a partial agonist at dopamine D2 receptors. Used for Schizophrenia, Major depressive disorder as adjunctive therapy.
At a glance
| Generic name | OPC-34712 [Brexpiprazole] High Dose |
|---|---|
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Drug class | Atypical antipsychotic |
| Target | 5-HT1A receptor, D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
This dual action is thought to contribute to its therapeutic effects in treating schizophrenia and bipolar disorder. By modulating these receptors, brexpiprazole may help to improve mood and reduce symptoms of psychosis.
Approved indications
- Schizophrenia
- Major depressive disorder as adjunctive therapy
Common side effects
- Weight gain
- Headache
- Nausea
- Dizziness
- Somnolence
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: